(+/-)-cis-2-methyl-cyclopropane-carboxylic acid-(1)-amide | 1759-49-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+/-)-cis-2-methyl-cyclopropane-carboxylic acid-(1)-amide
• 英文别名: (+/-)-cis-2-Methyl-cyclopropan-carbonsaeure-(1)-amid；(+/-)-cis-<2-Methyl-cyclopropyl>-carbonsaeureamid；(1R,2S)-2-methylcyclopropane-1-carboxamide
• CAS: 1759-49-5；6142-58-1；81428-99-1；107912-92-5；107912-93-6
• 化学式: C₅H₉NO
• 分子量: 99.1326
• InChiKey: FGJUPRFXIMWVNF-IUYQGCFVSA-N

物化性质

• 熔点：
  110 °C
• 沸点：
  235.5±7.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (+/-)-cis-2-methyl-cyclopropane-carboxylic acid-(1)-amide 在 phosphorus pentoxide 作用下， 生成 (1S,2R)-2-Methyl-cyclopropanecarbonitrile
  参考文献：
  名称：

  Synthesis and absolute configurations of some optically active cis- and trans-1,2-disubstituted cyclopropanes

  摘要：

  DOI：

  10.1021/ja01054a032
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 (+/-)-cis-2-methyl-cyclopropane-carboxylic acid-(1)-amide
  参考文献：
  名称：

  Substituted Butyronitriles. 2-Methylcyclopropanecarbonitrile and the Synthesis of Pyrrolines from γ-Cyanopropyl Ethers

  摘要：

  DOI：

  10.1021/ja01225a057

文献信息

• Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
  申请人：Artman D. Linda

  公开号：US20060025477A1

  公开（公告）日：2006-02-02

  An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.

  一种异戊酰胺类似物，相比异戊酰胺，至少具有增强的效力、延长的半衰期和增强的稳定性中的一种。该异戊酰胺类似物是环状类似物或非环状类似物。该异戊酰胺类似物被制成药物组合物。还揭示了一种治疗中枢神经系统疾病或疾病的方法。该方法包括向患有中枢神经系统疾病或疾病的患者施用异戊酰胺类似物。
• Enantioselective synthesis of curacin A. 1. Construction of C1–C7, C8–17, and C18–C22 segments
  作者：Hisanaka Ito、Nobuyuki Imai、Shin Tanikawa、Susumu Kobayashi

  DOI：10.1016/0040-4039(96)00030-5

  日期：1996.3

  Total synthesis of curacin A, a novel antimitotic antiproliferative antibiotic, was achieved by the connection of C1C7, C8C17, and C18C22 segments. Enantioselective preparation of each segments were accomplished by asymmetric allylation, chiral synthon method, and asymmetric hydrolysis by using pig liver esterase, respectively.

  通过连接C1C7，C8C17和C18C22片段，实现了新的抗有丝分裂抗增殖抗生素curacin A的全合成。每个片段的对映选择性制备分别通过不对称烯丙基化，手性合成子法和使用猪肝酯酶的不对称水解完成。
• Enantioselective synthesis of curacin A. 2. Total synthesis of curacin A by condensation of C1–C7, C8–C17, and C18–C22 segments
  作者：Hisanaka Ito、Nobuyuki Imai、Ken-ichi Takao、Susumu Kobayashi

  DOI：10.1016/0040-4039(96)00031-7

  日期：1996.3

  Total synthesis of curacin A, a novel antimitotic antiproliferative antibiotic, was achieved by the connection of C1C7, C8C17, and C18C22 segments by Julia coupling and iminoether condensation.

  合成新的抗有丝分裂抗增殖抗生素curacin A的方法是，通过Julia偶联和亚氨基醚缩合将C1C7，C8C17和C18 achievedC22片段连接起来。
• Absolute Configuration and Total Synthesis of (+)-Curacin A, an Antiproliferative Agent from the Cyanobacterium <i>Lyngbya majuscula</i>
  作者：James D. White、Tae-Seong Kim、Mitch Nambu

  DOI：10.1021/ja9629874

  日期：1997.1.1

  The absolute configuration of curacin A was determined as (2R,13R,19R,21S)-1 by comparison of degradation products 2 and 3 with the same materials prepared by asymmetric synthesis. The total synthesis of 1 was completed from (1R,2S)-2-methylcyclopropanecarboxylic acid (8) and the amino alcohol derivative 46. The latter was prepared from 4-pentynal (14) and the Garner aldehyde (43). Asymmetric allylation

  通过将降解产物 2 和 3 与通过不对称合成制备的相同材料进行比较，确定 curacin A 的绝对构型为 (2R,13R,19R,21S)-1。1的全合成由(1R,2S)-2-甲基环丙烷羧酸(8)和氨基醇衍生物46完成。后者由4-戊醛(14)和加纳醛(43)制备。14 的不对称烯丙基化，然后衍生的醇 16 的甲基化得到 17，将其进行锆化-碘化得到 18。后者与硼酸乙烯酯 21 偶联，后者由乙酸 4-戊炔酯 (20) 制备，在Pd(0)和所得三烯醇22被转化为碘化鏻24。来自24的叶立德与43的Wittig反应提供四烯44，其在甲醇分解时产生45。
• Inhibition of the mammalian .beta.-lactamase renal dipeptidase (dehydropeptidase-I) by Z-2-(acylamino)-3-substituted-propenoic acids
  作者：Donald W. Graham、Wallace T. Ashton、Louis Barash、Jeannette E. Brown、Ronald D. Brown、Laura F. Canning、Anna Chen、James P. Springer、Edward F. Rogers

  DOI：10.1021/jm00389a018

  日期：1987.6

  The title enzyme deactivates the potent carbapenem antibiotic imipenem in the kidney, producing low antibiotic levels in the urinary tract. A series of (Z)-2-(acylamino)-3-substituted-propenoic acids (3) are specific, competitive inhibitors of the enzyme capable of increasing the urinary concentration of imipenem in vivo. Many of the compounds were prepared in one step from an alpha-keto acid and a primary amide. The optimum R2 groups are 2,2-dimethyl, -dichloro, and -dibromocyclopropyl. With R2 = 2,2-dimethylcyclopropyl (DMCP), a wide variety of R3 groups including alkyl, oxa- and thiaalkyl, and alkyl groups containing acidic, basic, and neutral substituents give effective inhibitors with Ki values of 0.02-1 microM and a range of pharmacokinetic properties. By resolution of enantiomers and X-ray crystallography, the enzyme-inhibitory activity of the DMCP group was found to reside with the 1S isomer. The cysteinyl compound 176 (cilastatin, MK-0791) has the desired pharmacological properties and has been chosen for combination with imipenem.